Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACRV
STRONG SELLAcrivon Therapeutics, Inc. · Healthcare · United States · $68M · Avg Vol: $692K/d
COMPANY DESCRIPTION
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Acrivon Predictive Precision Medicine (APPM) platform to develop targeted oncology therapeutics. The platform enables the identification of patient-specific protein biomarkers to predict drug response, matching the right patient with the right therapy. Acrivon's competitive moat is defined by this precision medicine approach, which aims to significantly increase clinical trial success rates for its pipeline candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 0.1M | — |
| EPS | -7.56 | -2.74 | -2.38 | -2.02 | — | -1.99 | -2.07 | -1.95 | — |
| Shares | 21.9M | 22.5M | 31.2M | 31.6M | +44.4% | — | — | — | — |
| Debt | 5.0M | 4.6M | 3.6M | 2.7M | -18.3% | 2.4M | — | — | — |
| Equity | 170.5M | 121.2M | 176.8M | 112.5M | -12.9% | — | — | — | — |
| Op CF | -30.1M | -42.6M | -65.7M | -63.7M | — | -64.7M | — | — | — |
| Inv CF | -141.7M | 50.7M | -51.8M | 66.1M | — | — | — | — | — |
| Fin CF | 101.7M | -1.6M | 121.0M | -0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACRV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc.(you) | $68M | 15 | STRONG SELL |
| OSTX | OS Therapies Incorporated | $68M | 16 | STRONG SELL |
| MNOV | MediciNova, Inc. | $65M | 16 | STRONG SELL |
| PLRX | Pliant Therapeutics, Inc. | $67M | 19 | STRONG SELL |
| VRCA | Verrica Pharmaceuticals Inc. | $86M | 15 | STRONG SELL |
| IMA | ImageneBio, Inc. | $63M | 12 | STRONG SELL |
| MAIA | MAIA Biotechnology, Inc. | $75M | 12 | STRONG SELL |
| CING | Cingulate Inc. | $62M | 12 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $58M | 13 | STRONG SELL |
| ACET | Adicet Bio, Inc. | $73M | 20 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%